Summary & Overview
CPT 86363: MOG–IgG1 Antibody Test by Flow Cytometry
CPT code 86363 denotes a laboratory assay for detection of MOG–IgG1 antibodies using fluorescence–activated cell sorting (FACS) flow cytometry on serum. This test has clinical importance in neuroimmunology: it aids in differentiating neuromyelitis optica spectrum disorders from MOG–encephalomyelitis when aquaporin‑4 antibody testing is negative. Nationwide, availability and coding clarity affect billing, access to specialized testing, and case identification for rare demyelinating disorders.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of clinical context, typical site-of-service considerations, and the code’s role in diagnostic pathways for demyelinating disease. The publication also outlines expected service type and testing modality, common billing modifiers and technical components when present, and where data was not available for associated taxonomies, ICD-10 diagnoses, or related codes.
This summary is designed to inform laboratory managers, billing professionals, and clinicians about CPT code 86363—its clinical rationale, typical use cases, and payer relevance—so stakeholders can align documentation, ordering practices, and claims submission with the test’s intended purpose.
Billing Code Overview
CPT code 86363 describes a laboratory test to detect myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG–IgG1) antibodies, typically performed on a serum specimen. The test method specified for this code is fluorescence–activated cell sorting (FACS) using flow cytometry.
Service Type: Laboratory serologic antibody test
Typical Site of Service: Clinical laboratory or hospital outpatient laboratory
Clinical context: Clinicians order this assay to help distinguish neuromyelitis optica (NMO) from MOG–encephalomyelitis (MOG–EM), often following a negative aquaporin–4 antibody test.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 34-year-old woman presents to a neurology clinic with subacute bilateral optic neuritis and thoracic transverse myelitis. Brain and spine MRI show lesions suggestive of an inflammatory demyelinating disorder. Serum testing for aquaporin-4 antibody is negative. The neurologist orders testing for myelin oligodendrocyte glycoprotein immunoglobulin G1 using flow cytometry (MOG–IgG1 by FACS, 86363) to distinguish MOG–encephalomyelitis from aquaporin-4–positive neuromyelitis optica spectrum disorder.
The clinical workflow: outpatient neurology visit → blood draw for serum specimen → specimen labeled and sent to the clinical immunology laboratory → laboratory performs MOG–IgG1 testing by fluorescence-activated cell sorting (flow cytometry) using established assay controls → results reported to ordering clinician and entered into the electronic medical record. Testing may be ordered after initial negative aquaporin-4 antibody testing or when clinical phenotype (optic neuritis, myelitis, ADEM-like syndrome) suggests MOG-related disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the physician interpretation/report portion separated from the technical lab component. |